DexCom price target raised to $110 from $103 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on DexCom to $110 from $103 and keeps an Equal Weight rating on the shares post the Q4 results. The company delivered Q4 sales and a 2023 outlook in-line with its preannouncement, the analyst tells investors in a research note.